Jazz Pharmaceuticals Announces First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cantor Fitzgerald Loweres PT to $165 for Jazz Pharmaceuticals (JAZZ) Following 1Q15 EPS Miss
May 11, 2015 7:52 AM EDTCantor Fitzgerald reiterates their Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and lowered the price target to $165.00 (from $175.00) following a 1Q15 EPS miss. JAZZ reported in-line revenue of $309M, but missed the adjusted diluted EPS with $1.99 (vs. $2.14 estimates). Cantor Fitzgerald said that they... More
Guggenheim Securities Remains Bullish in Wake of Jazz Pharmaceuticals (JAZZ) 1Q15 EPS Miss
May 8, 2015 8:46 AM EDTGuggenheim Securities maintains a Buy status on Jazz Pharmaceuticals, PLC (NASDAQ: JAZZ), with a price target set at $210. This follows an EPS miss from JAZZ in 1Q15. JAZZ reported 1Q15 adjusted diluted EPS of $1.99. This came in $0.15 lower than consensus and $0.18 lower than Guggenheim estimated. Guggenheim believes that... More
Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 15c
May 7, 2015 4:16 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $1.99, $0.15 worse than the analyst estimate of $2.14. Revenue for the quarter came in at $309.3 million versus the consensus estimate of $308.92 million.
Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.75, versus the consensus of $9.77. Jazz Pharmaceuticals sees FY2015... More
